Observers warn of the negative health consequences if US President Donald Trump follows through on his promise to impose tariffs on pharmaceuticals. Susan Jaffe reports.

This week, underscoring a commitment to national security, the White House and the Food and Drug Administration (FDA) issued separate communications that aim to bolster domestic drug manufacturing ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Imports of pharmaceutical products surged in March, most of which came from Ireland, historically one of the biggest ...

Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products, which have historically been exempt from such fees.

The Trump administration May 5 issued two executive orders on pharmaceutical manufacturing and life-sciences research.

Federal agencies, including the FDA and the EPA, were ordered to accelerate approval of domestic manufacturing plants.

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

FDA Commissioner Marty Makary’s proposal to roll out a new drug approval pathway is heightening hope for the rare disease ...

President Donald Trump on Monday signed an executive order to incentivize prescription drug manufacturing in the U.S., ...

is seeking to attach conditions to the length of this period in order to push companies to roll out new medicines in poorer and smaller EU states more quickly. Pharmaceutical companies have ...